The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groups
| Autor: | G. Barbieri, F Meucci, Giuseppe Turchetti, F Saia, Valentina Lorenzoni, P Candolfi, S Berti, G L Martinelli, A G Cerillo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Cost effectiveness Cost-Benefit Analysis Economics Econometrics and Finance (miscellaneous) Time horizon Economic 030204 cardiovascular system & hematology Transcatheter Aortic Valve Replacement 03 medical and health sciences Indirect costs 0302 clinical medicine Aortic valve replacement medicine Humans 030212 general & internal medicine Stroke health care economics and organizations Heart Valve Prosthesis Implantation Original Paper Transcatheter aortic valve implantation Health economics I18 business.industry Health Policy Aortic stenosis I12 Univariate Aortic Valve Stenosis medicine.disease Quality-adjusted life year Treatment Outcome Italy Cost-effectiveness Emergency medicine Quality-Adjusted Life Years business |
| Zdroj: | The European Journal of Health Economics |
| ISSN: | 1618-7601 1618-7598 |
| Popis: | Objectives To assess the cost-effectiveness (CE) of transcatheter aortic valve implantation (TAVI) in Italy, considering patient groups with different surgical risk. Methods A Markov model with a 1-month cycle length, comprising eight different health states, defined by the New York Heart Association functional classes (NYHA I–IV), with and without stroke plus death, was used to estimate the CE of TAVI for intermediate-, high-risk and inoperable patients considering surgical aortic valve replacement or medical treatment as comparators according to the patient group. The Italian National Health System perspective and 15-year time horizon were considered. In the base-case analysis, effectiveness data were retrieved from published efficacy data and total direct costs (euros) were estimated from national tariffs. A scenario analysis considering a micro-costing approach to estimate procedural costs was also considered. The incremental cost-effectiveness ratio (ICER) was expressed both in terms of costs per life years gained (LYG) and costs per quality adjusted life years (QALY). All outcomes and costs were discounted at 3% per annum. Univariate and probabilistic sensitivity analyses (PSA) were performed to assess robustness of results. Results Over a 15-year time horizon, the higher acquisition costs for TAVI were partially offset in all risk groups because of its effectiveness and safety profile. ICERs were €8338/QALY, €11,209/QALY and €10,133/QALY, respectively, for intermediate-, high-risk and inoperable patients. ICER values were slightly higher in the scenario analysis. PSA suggested consistency of results. Conclusions TAVI would be considered cost-effective at frequently cited willingness-to-pay thresholds; further studies could clarify the CE of TAVI in real-life scenarios. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink